Novartis
NVS
HK$971.86
Share price
0.58%
Change (1 day)
16.93%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Novartis (NVS) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : HK$482.66 Billion
According to Novartis's latest financial reports the company's total liabilities are HK$482.66 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Novartis - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | HK$451.21 B | 8.61% |
| 2023-12-31 | HK$415.45 B | -8.37% |
| 2022-12-31 | HK$453.40 B | -9.11% |
| 2021-12-31 | HK$498.83 B | -9.51% |
| 2020-12-31 | HK$551.27 B | 12.68% |
| 2019-12-31 | HK$489.24 B | -6.57% |
| 2018-12-31 | HK$523.66 B | 13.89% |
| 2017-12-31 | HK$459.80 B | 7.35% |
| 2016-12-31 | HK$428.30 B | 1.52% |
| 2015-12-31 | HK$421.90 B | -0.27% |
| 2014-12-31 | HK$423.06 B | 5.36% |
| 2013-12-31 | HK$401.53 B | -5.69% |
| 2012-12-31 | HK$425.75 B | 6.33% |
| 2011-12-31 | HK$400.43 B | -3.91% |
| 2010-12-31 | HK$416.72 B | 41.28% |
| 2009-12-31 | HK$294.97 B | 37% |
| 2008-12-31 | HK$215.30 B | 5.98% |
| 2007-12-31 | HK$203.15 B | -2.22% |
| 2006-12-31 | HK$207.76 B | 9.07% |
| 2005-12-31 | HK$190.48 B | 15.77% |
| 2004-12-31 | HK$164.53 B | 12.92% |
| 2003-12-31 | HK$145.70 B | 11.95% |
| 2002-12-31 | HK$130.15 B | 13.19% |
| 2001-12-31 | HK$114.99 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Merck MRK | HK$523.74 B | 8.51% | 🇺🇸 USA |
 Pfizer PFE | HK$921.47 B | 90.91% | 🇺🇸 USA |
 Johnson & Johnson JNJ | HK$907.11 B | 87.94% | 🇺🇸 USA |
 Sanofi SNY | HK$488.09 B | 1.12% | 🇫🇷 France |
 GlaxoSmithKline GSK | HK$477.20 B | -1.13% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | HK$252.33 B | -47.72% | 🇮🇱 Israel |
 Bristol-Myers Squibb BMY | HK$588.55 B | 21.94% | 🇺🇸 USA |
 Abbott Laboratories ABT | HK$254.20 B | -47.33% | 🇺🇸 USA |
 AstraZeneca AZN | HK$511.18 B | 5.91% | 🇬🇧 UK |